ANSWER: C

Rationale:

The hypothalamus controls GH secretion through two opposing peptide signals. Growth hormone-releasing hormone (GHRH) stimulates GH secretion: it binds the GHRH receptor on pituitary somatotrophs and drives GH synthesis and release. Somatostatin (somatotropin release-inhibiting factor) inhibits GH secretion: it binds somatostatin receptors on somatotrophs and suppresses GH release. The magnitude of each GH pulse reflects the balance between GHRH drive and somatostatin tone; the largest GH pulses occur during slow-wave sleep when somatostatin tone falls and GHRH release peaks simultaneously.

• Option A: Option A is incorrect because it reverses the two effects: GHRH stimulates rather than inhibits, and somatostatin inhibits rather than stimulates.
• Option B: Option B is incorrect because GHRH and somatostatin have opposite effects, not the same stimulatory effect; somatostatin suppresses GH.
• Option D: Option D is incorrect because GHRH stimulates GH secretion and is not inhibitory; while ghrelin does provide a third, stimulatory input through the GH secretagogue receptor, GHRH is also stimulatory, so the claim that ghrelin is the sole stimulatory input is wrong.
• Option E: Option E is incorrect because somatostatin inhibits GH secretion at all times and does not become stimulatory during slow-wave sleep; the larger GH pulses during slow-wave sleep result from withdrawal of somatostatin tone combined with peak GHRH release, not from somatostatin becoming stimulatory.

ANSWER: A

Rationale:

Native somatostatin-14 has an extremely short plasma half-life of approximately 1 to 3 minutes because it is rapidly degraded by peptidases, which makes it impractical as a therapeutic agent. Octreotide is a synthetic octapeptide analog engineered for metabolic stability; its plasma half-life is approximately 1.5 to 2 hours, roughly 200-fold longer than native somatostatin-14. This prolonged half-life is what makes octreotide clinically useful, allowing intermittent subcutaneous dosing rather than continuous infusion.

• Option B: Option B is incorrect because octreotide has a longer, not shorter, half-life than native somatostatin; the entire purpose of the analog is to extend duration of action, not shorten it.
• Option C: Option C is incorrect because the half-lives are not identical — octreotide's half-life is far longer — and octreotide is not orally bioavailable; like native somatostatin it is a peptide degraded in the gastrointestinal tract and must be given parenterally.
• Option D: Option D is incorrect because octreotide's half-life is approximately 1.5 to 2 hours, not several days; native somatostatin-14 does not have a multi-day half-life either, and neither immediate-release form is dosed once weekly.
• Option E: Option E is incorrect because octreotide is not structurally identical to native somatostatin-14 — it is a shortened octapeptide analog — and it is not a prodrug requiring hepatic activation; it is pharmacologically active as administered.

ANSWER: D

Rationale:

Octreotide LAR (Sandostatin LAR) is formulated as poly(lactic-co-glycolic acid) (PLGA) polymer microspheres that encapsulate octreotide and is administered by intramuscular (IM) injection every 28 days. Lanreotide Autogel (Somatuline Depot) is formulated as a high-viscosity aqueous gel delivered by deep subcutaneous (SC) injection using a pre-filled syringe, also every 28 days. The two depot products therefore differ in both formulation (microspheres versus aqueous gel) and route (IM versus deep SC).

• Option A: Option A is incorrect because it reverses the two products: octreotide LAR uses microspheres given IM, and lanreotide Autogel uses an aqueous gel given deep SC, the opposite of what is stated.
• Option B: Option B is incorrect because neither depot is given by intravenous infusion; octreotide LAR is given IM and lanreotide Autogel is given deep SC.
• Option C: Option C is incorrect because neither product is an oral tablet; both are peptide analogs that would be degraded in the gastrointestinal tract and must be given parenterally.
• Option E: Option E is incorrect because octreotide LAR is the long-acting depot given every 28 days, not a daily SC injection (the daily SC form is plain octreotide, not octreotide LAR), and lanreotide Autogel is a deep SC gel depot, not a surgically implanted six-month pellet.

ANSWER: B

Rationale:

Pasireotide is a pan-somatostatin receptor (pan-SSTR) agonist that binds SSTR1, SSTR2, SSTR3, and SSTR5 with high affinity; its affinity for SSTR5 is approximately 40-fold greater than that of octreotide. Octreotide, by contrast, is more selective: it binds primarily SSTR2 and SSTR5 (with moderate SSTR3 affinity and negligible SSTR1 and SSTR4 binding). This broader receptor coverage is the basis for pasireotide's efficacy in some patients not controlled by octreotide.

• Option A: Option A is incorrect because pasireotide does not bind only SSTR2 — it binds four subtypes — and octreotide does not bind all five subtypes with equal affinity; octreotide has negligible affinity for SSTR1 and SSTR4.
• Option C: Option C is incorrect because the two agents do not have identical profiles; pasireotide binds a broader set of subtypes (including SSTR1 and SSTR3) than octreotide.
• Option D: Option D is incorrect because pasireotide does not bind only SSTR4; in fact SSTR4 is not a clinically significant target for either agent, and pasireotide's defining feature is its broad SSTR1/2/3/5 binding.
• Option E: Option E is incorrect because it reverses the two agents: pasireotide is the pan-SSTR agonist and octreotide is the more selective agent, not the other way around.

ANSWER: E

Rationale:

Pasireotide carries a substantially higher risk of treatment-emergent hyperglycemia than the first-generation SSAs octreotide and lanreotide. Hyperglycemia occurs in roughly 57 to 73% of pasireotide-treated patients, compared with about 10 to 20% for the SSTR2-selective agents. The mechanism is pasireotide's high affinity for SSTR5 (somatostatin receptor subtype 5), which profoundly suppresses both insulin secretion from pancreatic beta cells and incretin hormone release (GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)) from intestinal cells. The dominant defect is reduced insulin secretion rather than increased insulin resistance.

• Option A: Option A is incorrect because octreotide is associated with a substantially lower hyperglycemia risk than pasireotide; its SSTR2-selective profile causes less profound suppression of insulin and incretin secretion.
• Option B: Option B is incorrect because lanreotide is a first-generation SSTR2/SSTR5 agent with a hyperglycemia risk comparable to octreotide, not the highest; its gel formulation affects pharmacokinetics, not receptor-driven glycemic risk, and SSTR3 is not the basis of SSA hyperglycemia.
• Option C: Option C is incorrect because the three agents do not share identical receptor binding profiles; pasireotide's broader and higher-affinity SSTR5 binding makes its hyperglycemia risk distinctly greater.
• Option D: Option D is incorrect because SSAs characteristically cause hyperglycemia (predominantly through insulin suppression), not consistent hypoglycemia; they suppress insulin secretion rather than enhance it.

ANSWER: C

Rationale:

Sermorelin (GHRH 1-29 NH2) is a synthetic peptide comprising the biologically active N-terminal 29 amino acids of native growth hormone-releasing hormone (GHRH), which is a 44-amino acid peptide. The first 29 residues retain full GH-releasing activity, so sermorelin acts at the GHRH receptor on pituitary somatotrophs to stimulate endogenous GH release in a physiological pulsatile pattern. Because it acts upstream of the pituitary, it requires an intact somatotroph pool to be effective.

• Option A: Option A is incorrect because sermorelin is a GHRH analog that stimulates GH release, not a somatostatin analog that suppresses it; somatostatin-14 is an entirely different peptide.
• Option B: Option B is incorrect because the recombinant full-length 191-amino acid GH molecule is somatropin, not sermorelin; sermorelin is a GHRH fragment, not GH itself.
• Option D: Option D is incorrect because the orally bioavailable small-molecule ghrelin receptor (GHSR-1a) agonist is macimorelin, not sermorelin; sermorelin is an injectable GHRH peptide fragment.
• Option E: Option E is incorrect because the pegylated growth hormone receptor antagonist is pegvisomant, not sermorelin; sermorelin stimulates rather than blocks the GH axis.

ANSWER: A

Rationale:

Tesamorelin is a synthetic analog of GHRH (the full 44-amino acid sequence) stabilized by an N-terminal trans-3-hexenoic acid modification that protects it from cleavage by dipeptidyl peptidase-4 (DPP-4), extending its half-life. It stimulates endogenous GH release and is FDA-approved specifically for the reduction of excess visceral adipose tissue (VAT) in HIV (human immunodeficiency virus)-infected patients with antiretroviral therapy-associated lipodystrophy.

• Option B: Option B is incorrect because tesamorelin is a GHRH analog (which stimulates the GH axis), not a somatostatin receptor analog (which suppresses it), and it is not used for acromegaly; using a GH-stimulating agent in acromegaly would be counterproductive.
• Option C: Option C is incorrect because the growth hormone receptor antagonist used to normalize IGF-1 in resistant acromegaly is pegvisomant, not tesamorelin.
• Option D: Option D is incorrect because the recombinant human GH preparation used for pediatric growth failure is somatropin, not tesamorelin; tesamorelin stimulates endogenous GH rather than replacing it.
• Option E: Option E is incorrect because the oral ghrelin receptor agonist used as a diagnostic agent for adult GH deficiency is macimorelin, not tesamorelin; tesamorelin is an injectable therapeutic GHRH analog, not a diagnostic agent.

ANSWER: D

Rationale:

Macimorelin (Macrilen) is an orally bioavailable small-molecule agonist at the ghrelin receptor (GHSR-1a, growth hormone secretagogue receptor type 1a). It is approved as a diagnostic stimulation agent for adult GH deficiency: after a single oral dose, peak GH is measured, and a GH peak below 2.8 ng/mL establishes the diagnosis. Its oral route and absence of hypoglycemia risk make it a practical and safer alternative to insulin tolerance testing.

• Option A: Option A is incorrect because macimorelin stimulates rather than suppresses the GH axis and is not a somatostatin receptor analog; it is also oral, not injectable.
• Option B: Option B is incorrect because the recombinant GH preparation given for replacement is somatropin, not macimorelin; macimorelin is a diagnostic secretagogue, not a replacement hormone.
• Option C: Option C is incorrect because macimorelin is an oral ghrelin receptor agonist, not an injectable GHRH analog, and it is a diagnostic agent rather than a therapeutic growth-promoting treatment for children.
• Option E: Option E is incorrect because the GH receptor antagonist used in resistant acromegaly is pegvisomant, not macimorelin; macimorelin is a diagnostic ghrelin receptor agonist, not a therapeutic antagonist.

ANSWER: B

Rationale:

Somatropin is recombinant human growth hormone (rhGH), a 191-amino acid single-chain polypeptide produced by recombinant DNA technology. Because it is a peptide hormone that would be degraded by gastrointestinal proteases, it cannot be taken orally and is administered parenterally, nearly always by subcutaneous (SC) injection. It directly replaces GH in deficiency states.

• Option A: Option A is incorrect because somatropin is full-length GH itself, not a GHRH fragment that stimulates endogenous release, and it is injected rather than taken orally; the GHRH fragment that stimulates endogenous GH is sermorelin.
• Option C: Option C is incorrect because somatropin replaces GH and is not a somatostatin receptor analog; it does not suppress GH, and it is given by daily SC injection rather than as a GH-suppressing IM depot.
• Option D: Option D is incorrect because the growth hormone receptor antagonist is pegvisomant (which is injected, not oral), whereas somatropin is the GH agonist used for replacement.
• Option E: Option E is incorrect because the oral ghrelin receptor agonist is macimorelin (a diagnostic agent), not somatropin; somatropin is recombinant GH given by injection.

ANSWER: E

Rationale:

Pegvisomant and the somatostatin receptor analogs (SSAs) lower IGF-1 by mechanistically opposite strategies. SSAs (octreotide, lanreotide, pasireotide) act at the pituitary somatotroph, where somatostatin receptor agonism suppresses GH secretion. Pegvisomant acts at the periphery: it is a growth hormone receptor (GHR) antagonist that blocks GH action at target tissues (notably the liver), preventing IGF-1 generation, without suppressing pituitary GH output. Because it does not suppress the pituitary and it removes IGF-1 negative feedback, serum GH actually rises during pegvisomant therapy.

• Option A: Option A is incorrect because pegvisomant does not act through somatostatin receptor agonism at the pituitary; only the SSAs do.
• Option B: Option B is incorrect because pegvisomant does not suppress pituitary GH secretion at all — GH rises rather than falls during therapy, so GH is not a useful monitoring marker.
• Option C: Option C is incorrect because pegvisomant does not stimulate hypothalamic somatostatin release; it is a peripheral receptor antagonist.
• Option D: Option D is incorrect because SSAs are not growth hormone receptor antagonists; they are somatostatin receptor agonists acting at the pituitary, so only pegvisomant fits the GHR-antagonist description.

ANSWER: C

Rationale:

During pegvisomant therapy, serum IGF-1 (insulin-like growth factor-1) is the sole reliable monitoring marker. Pegvisomant blocks the GH receptor at peripheral tissues, lowering IGF-1 generation, but it does not suppress pituitary GH secretion. Because IGF-1 normally exerts negative feedback on the pituitary, the fall in IGF-1 disinhibits the somatotroph and serum GH actually rises during therapy. Serum GH is therefore uninformative and potentially misleading; only IGF-1 reflects treatment adequacy.

• Option A: Option A is incorrect because serum GH does not fall during pegvisomant therapy — it rises — so GH is not a valid monitoring marker for this agent.
• Option B: Option B is incorrect because GH and IGF-1 do not fall in parallel during pegvisomant therapy; they dissociate, with IGF-1 falling while GH rises.
• Option D: Option D is incorrect because serum prolactin does not track GH receptor blockade and is not the monitoring marker for pegvisomant; IGF-1 is.
• Option E: Option E is incorrect because IGF-1 is a useful and indeed essential laboratory marker for pegvisomant monitoring; while pituitary imaging is performed periodically because pegvisomant does not shrink tumor, biochemical response is monitored with IGF-1, not by imaging alone.

ANSWER: A

Rationale:

Lanreotide is eliminated predominantly by the fecal (biliary) route, with less than 5% of the drug excreted unchanged in the urine. Because renal excretion contributes so little to its clearance, dose adjustment is generally not required in patients with renal impairment.

• Option B: Option B is incorrect because lanreotide is not eliminated primarily by renal excretion; its clearance is predominantly biliary/fecal, so a renal-impairment dose reduction is not generally needed.
• Option C: Option C is incorrect because lanreotide is a peptide depot drug and is not eliminated by exhalation as a volatile metabolite; pulmonary elimination plays no role.
• Option D: Option D is incorrect because lanreotide is administered parenterally specifically to avoid first-pass hepatic metabolism and is not converted to a renally cleared active metabolite; its elimination is predominantly biliary/fecal.
• Option E: Option E is incorrect because lanreotide is eliminated from the body (predominantly by the biliary/fecal route) and is dosed repeatedly (every 28 days, with extended intervals in controlled patients), not as a single lifetime dose.

ANSWER: D

Rationale:

Pegvisomant acts peripherally at the GH receptor and does not act on the pituitary tumor; consequently it does not reduce pituitary tumor volume, and pituitary imaging is monitored periodically during pegvisomant therapy because tumor growth is not prevented by the drug. By contrast, somatostatin receptor analogs (SSAs) act at the pituitary somatotroph and can produce tumor shrinkage in a meaningful proportion of patients. This makes SSAs preferable when tumor mass effect — such as visual field compromise from compression — needs to be controlled medically.

• Option A: Option A is incorrect because the two agents do not have equivalent effects on tumor volume; SSAs can shrink tumor while pegvisomant does not.
• Option B: Option B is incorrect because pegvisomant does not shrink tumor at all, so it is not preferred when mass effect threatens vision; SSAs (or surgery) are favored in that setting.
• Option C: Option C is incorrect because SSAs do affect tumor volume — they can shrink it — so the claim that neither medical agent alters tumor size is wrong.
• Option E: Option E is incorrect because SSAs do not cause tumors to enlarge; they can shrink them, and pegvisomant does not specifically prevent tumor growth — it has no tumor-volume effect.

ANSWER: B

Rationale:

The principal safety advantage of the macimorelin stimulation test is that it does not induce hypoglycemia. Insulin tolerance testing (ITT) works by deliberately inducing hypoglycemia (glucose below 40 mg/dL) as the stimulus for GH release, which carries real risk and is contraindicated in patients with seizure disorders, cardiovascular disease, and older age. Macimorelin, an oral ghrelin receptor agonist, stimulates GH through an insulin-independent pathway and therefore avoids hypoglycemia entirely, making it safer and more practical while offering sensitivity and specificity comparable to ITT.

• Option A: Option A is incorrect because macimorelin does not produce hypoglycemia at all; the advantage is the absence of hypoglycemia, not a deeper hypoglycemic stimulus.
• Option C: Option C is incorrect because macimorelin does not work by inducing hyperglycemia; it stimulates GH via the ghrelin receptor without altering glucose as the stimulus.
• Option D: Option D is incorrect because macimorelin testing is a simple oral test that does not require general anesthesia; its safety derives from avoiding hypoglycemia, not from anesthesia.
• Option E: Option E is incorrect because the two tests do not have identical safety profiles — ITT carries hypoglycemia risk that macimorelin avoids — so the preference for macimorelin is based on safety, not merely cost.

ANSWER: E

Rationale:

The most important safety concern with pegvisomant is hepatotoxicity. Clinically significant elevations of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) occur in roughly 5 to 8% of patients. The monitoring requirement is measurement of liver function tests (ALT, AST, bilirubin) at baseline and periodically during therapy (every 6 months), with more frequent monitoring if transaminases exceed three times the upper limit of normal and discontinuation of the drug if they exceed five times the upper limit of normal.

• Option A: Option A is incorrect because hypoglycemia is not pegvisomant's principal safety concern; the agent associated with prominent glycemic effects is pasireotide (hyperglycemia), and pegvisomant's defining concern is hepatotoxicity.
• Option B: Option B is incorrect because QT-interval prolongation is a concern with the macimorelin diagnostic test, not the principal safety concern of pegvisomant.
• Option C: Option C is incorrect because gallstone formation is the characteristic long-term concern with the somatostatin receptor analogs (through cholecystokinin suppression), not with pegvisomant.
• Option D: Option D is incorrect because severe hyperglycemia is the hallmark adverse effect of pasireotide, not pegvisomant; pegvisomant's principal concern is hepatotoxicity monitored with liver function tests.

ANSWER: D

Rationale:

Cholelithiasis is a well-recognized long-term adverse effect of the somatostatin receptor analogs (SSAs) — octreotide, lanreotide, and pasireotide. The mechanism is suppression of cholecystokinin (CCK) release and inhibition of gallbladder contractility; CCK normally drives postprandial gallbladder emptying, so its suppression leads to bile stasis, which promotes cholesterol supersaturation and gallstone formation. Symptomatic gallstones develop in roughly 20 to 30% of patients on long-term SSA therapy, although only a small fraction require cholecystectomy.

• Option A: Option A is incorrect because somatropin (recombinant GH) is not the agent class associated with gallstone formation; the gallstone risk is a class effect of SSAs through CCK suppression, not a somatropin effect on biliary cholesterol synthesis.
• Option B: Option B is incorrect because pegvisomant is not associated with gallstone formation through GH receptor blockade on the gallbladder; the gallstone risk belongs to the SSAs.
• Option C: Option C is incorrect because SSAs reduce gallbladder contractility (causing stasis), and it is this reduction — not the excessive contraction attributed to GHRH analogs in the option — that causes stones; GHRH analogs are not the gallstone-associated class.
• Option E: Option E is incorrect because macimorelin is a single-dose diagnostic agent and is not associated with gallstone formation; the cholelithiasis risk is a long-term consequence of SSA therapy, not of a transient diagnostic test.